MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
13 Novembre 2023 - 6:00PM
Business Wire
Article 223-16 of the General Regulations of
the Financial Markets Authority (AMF - Autorité des Marchés
Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
improving survival outcomes for patients with cancer, today
published the number of shares comprising the share capital and the
total number of voting rights (Article L. 233-8 of the French
Commercial Code (Code de commerce) and Article 223-16 of the
General Regulations of French Autorité des Marchés Financiers
(AMF)) on October 31, 2023.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
Date
Total number of shares comprising
the share capital
Total number of theoretical
voting rights (1)
Total number of effective voting
rights (2)
10/31/2023
11 600 218
11 600 218
11 579 944
(1) In accordance with Article 223-11 of the AMF General
Regulation, this number is calculated on the basis of all shares to
which voting rights are attached, including shares whose voting
rights have been suspended.
(2) Effective voting rights correspond to the total number of
voting rights that may be used at a General Meeting. The total
number of effective voting rights is calculated without taking into
account the shares with suspended voting rights.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113252905/en/
MaaT Pharma – Investor Relations Guilhaume Debroas, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline Richaud Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Grafico Azioni Maat Pharma (EU:MAAT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Maat Pharma (EU:MAAT)
Storico
Da Set 2023 a Set 2024